Език: EN EN
← Назад към резултатите
Набира участници Не е приложимо NCT04294927

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

Не е приложима фаза (напр. обсервационно)
Заболявания: BRCA1 Gene Mutation BRCA2 Gene Mutation RAD51C Gene Mutation RAD51D Gene Mutation BRIP1 Gene Mutation Ovarian Cancer

Спонсор: University Medical Center Nijmegen

Налично на: БГ
Обобщение
The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.
Описание
In BRCA1/2 gene mutation carriers, a risk-reducing salpingo-oophorectomy (RRSO) is recommended around the age of 40. This recommendation is based on a 10-40% life-time risk of ovarian cancer in this population and disappointing results of ovarian cancer surveillance for early detection. Moreover, the mortality rate of ovarian cancer is high. Effects of RRSO are a decrease in ovarian cancer risk (80-96%) on one hand and immediate onset of menopause and non-cancer related morbidity on the other hand. The fifty percent breast cancer risk reduction after RRSO has become disputable in the last years. Based on multiple studies showing that most high-grade serous ovarian cancers develop at the distal end of the Fallopian tube, an innovative strategy for RRSO has been developed for this study proposal: risk-reducing salpingectomy (RRS) with delayed risk-reducing oophorectomy (RRO). However, the safety of this strategy has not been proven yet. Before implementing this innovative strategy as standard care we need to investigate the long term effects on ovarian cancer incidence.
Кой може да участва
Inclusion Criteria: * Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers. * Age at inclusion; * BRCA1: 25-40 years * BRCA2: 25-45 years * RAD51C, RAD51D, BRIP1: 25-50 years * Childbearing completed * Presence of at least one fallopian tube * Participants may have a personal history of non-ovarian malignancy * Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution. Exclusion Criteria: * Postmenopausal status (natural menopause or due to treatment) * Wish for second stage RRO within two years after RRS * Legally incapable * Prior bilateral salpingectomy * A personal history of ovarian, fallopian tube or peritoneal cancer * Current diagnosis or treatment for malignant disease
Места на провеждане 15
Австралия (1)
Chris O'Brien Lifehouse
Sydney , New South Wales
Белгия (1)
Hopital Universitaire Bruxelles
Brussels
Бразилия (1)
AC Camargo Cancer Centre
São Paulo
Канада (1)
Vancouver General Hospital
Vancouver
Германия (1)
Klinikum St. Marien Amberg
Amberg
NOT_YET_RECRUITING
Ireland (1)
Cork University Hospital
Cork
Италия (1)
Universita di Bologna
Bologna
Mexico (1)
Instituto Nacional de Cancerología
Mexico City
Нидерландия (1)
Radboudumc
Nijmegen , Gelderland
Норвегия (1)
Akershus University Hospital
Nordbyhagen
ACTIVE_NOT_RECRUITING
Полша (1)
Gdynia Oncology Centre
Gdynia
Испания (1)
Vall D'Hebron Barcelona
Barcelona
Швеция (1)
Karolinksa Institutet
Stockholm
САЩ (1)
UChicago Medicine
Chicago , Illinois
Uruguay (1)
Hospital Británico
Montevideo
Технически детайли
Статус
Набира участници
Фаза
Не е приложимо
Вид изследване
INTERVENTIONAL
Пол
Само жени
Минимална възраст
25 Years
Максимална възраст
50 Years
Здрави доброволци
Не
Начална дата
01.03.2020
Крайна дата
17.02.2040
Регистрационен номер
NCT04294927
Източник
anzctr
Запитване за медицински туризъм

Информацията е извлечена автоматично от ClinicalTrials.gov. Консултирайте се с вашия лекар преди да предприемете действия.